Real-world effectiveness and safety of baricitinib including its effect on biomarkers and laboratory data in Japanese adult patients with atopic dermatitis: a single-center retrospective study

被引：2

作者：

Watanabe, Ayu ^{[1
]}

Kamata, Masahiro ^{[1
]}

Okada, Yoshiki ^{[1
]}

Suzuki, Shoya ^{[1
]}

Ito, Makoto ^{[1
]}

Mizukawa, Itsumi ^{[1
]}

Uchida, Hideaki ^{[1
]}

Egawa, Shota ^{[1
]}

Chijiwa, Chika ^{[1
]}

Hiura, Azusa ^{[1
]}

Fukaya, Saki ^{[1
]}

Hayashi, Kotaro ^{[1
]}

Fukuyasu, Atsuko ^{[1
]}

Tanaka, Takamitsu ^{[1
]}

Ishikawa, Takeko ^{[1
]}

Tada, Yayoi ^{[1
]}

机构：

[1] Teikyo Univ, Sch Med, Dept Dermatol, Tokyo, Japan

来源：

JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY | 2024年 / 7卷

关键词：

atopic dermatitis; baricitinib; Janus kinase; Janus kinase inhibitor; real world data;

D O I：

10.3389/jcia.2024.12455

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Baricitinib demonstrated efficacy and tolerable safety in clinical trials for atopic dermatitis (AD); however, real-world data are limited. We examined effectiveness and safety of baricitinib, and laboratory data in AD patients treated with baricitinib in our department. We also evaluated baseline clinical severity in responders and non-responders. All adult AD patients treated with baricitinib in our department between January 2021 and February 2023 were included. Data on 30 Japanese AD patients were analyzed. Objective severity scores and patient-reported outcomes improved at one and 3 months, except for the affected body surface area at 1 month. The proportions of patients who achieved eczema area and severity index-50% improvement were 30.0% (9/30) at 1 month and 53.3% (16/30) at 3 months. There were no significant changes in AD biomarkers. No significant difference was observed in baseline clinical severity between responders and non-responders. No significant changes were observed in laboratory results except for increased serum creatine phosphokinase levels at 3 months. One case of herpes zoster and one case of ocular herpes were observed. Baricitinib showed mild effectiveness and favorable safety including laboratory findings. Biomarkers did not reflect clinical improvement. Further study is needed to identify characteristics of responders.

引用

页数：6

共 13 条

[1] Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials [J].

Bieber, T. ;

Thyssen, J. P. ;

Reich, K. ;

Simpson, E. L. ;

Katoh, N. ;

Torrelo, A. ;

De Bruin-Weller, M. ;

Thaci, D. ;

Bissonnette, R. ;

Gooderham, M. ;

Weisman, J. ;

Nunes, F. ;

Brinker, D. ;

Issa, M. ;

Holzwarth, K. ;

Gamalo, M. ;

Riedl, E. ;

Janes, J. .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (02) :476-485

[2] Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan [J].

Hagino, Teppei ;

Saeki, Hidehisa ;

Fujimoto, Eita ;

Kanda, Naoko .

JOURNAL OF DERMATOLOGY, 2023, 50 (07) :869-879

[3]

Kamata M, 2023, JID INNOV, V3, DOI [10.1016/j.xjidi.2023.100195, 10.1016/j.xjidi.2023.100195]

[4]

Kamata M, 2021, JID INNOV, V1, DOI [10.1016/j.xjidi.2021.100042, 10.1016/j.xjidi.2021.100042]

[5] Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials [J].

Katoh, Norito ;

Takita, Yasushi ;

Isaka, Yoshitaka ;

Nishikawa, Atsushi ;

Torisu-Itakura, Hitoe ;

Saeki, Hidehisa .

DERMATOLOGY AND THERAPY, 2022, 12 (12) :2765-2779

[6] Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis A Randomized Clinical Trial [J].

Reich, Kristian ;

Kabashima, Kenji ;

Peris, Ketty ;

Silverberg, Jonathan, I ;

Eichenfield, Lawrence F. ;

Bieber, Thomas ;

Kaszuba, Aleksandra ;

Kolodsick, Jill ;

Yang, Fan E. ;

Gamalo, Margaret ;

Brinker, Dennis R. ;

Delozier, Amy M. ;

Janes, Jonathan M. ;

Nunes, Fabio P. ;

Thyssen, Jacob P. ;

Simpson, Eric L. .

JAMA DERMATOLOGY, 2020, 156 (12) :1333-1343

[7] Long-term efficacy (up to 68 weeks) of Baricitinib in combination with topical corticosteroids in adult patients with moderate-to-severe atopic dermatitis: Analysis of treatment responders, partial responders and nonresponders originating from study BREEZE-AD7 [J].

Silverberg, Jonathan I. ;

Simpson, Eric L. ;

Thyssen, Jacob Pontoppidan ;

Werfel, Thomas ;

Cardillo, Tracy E. ;

Colvin, Stephanie ;

Pierce, Evangeline ;

Chen, Yun-Fei ;

Chen, Sherry ;

Eichenfield, Lawrence .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (05) :1036-1045

[8] Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phaseIIItrials [J].

Simpson, E. L. ;

Lacour, J. -P. ;

Spelman, L. ;

Galimberti, R. ;

Eichenfield, L. F. ;

Bissonnette, R. ;

King, B. A. ;

Thyssen, J. P. ;

Silverberg, J. I. ;

Bieber, T. ;

Kabashima, K. ;

Tsunemi, Y. ;

Costanzo, A. ;

Guttman-Yassky, E. ;

Beck, L. A. ;

Janes, J. M. ;

DeLozier, A. M. ;

Gamalo, M. ;

Brinker, D. R. ;

Cardillo, T. ;

Nunes, F. P. ;

Paller, A. S. ;

Wollenberg, A. ;

Reich, K. .

BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (02) :242-255

[9] Baseline Body Surface Area and Itch Severity Define Response to Baricitinib in Patients with Moderate-to-Severe Atopic Dermatitis at Week 16 [J].

Thyssen, Jacob P. ;

de Bruin-Weller, Marjolein ;

Costanzo, Antonio ;

Grond, Susanne ;

Schuster, Christopher ;

Liu, Chunyuan ;

Rueda, Maria Jose ;

Chen, Yun-Fei ;

Pinter, Andreas ;

Bieber, Thomas .

ADVANCES IN THERAPY, 2023, 40 (08) :3574-3587

[10] Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study [J].

Uchida, H. ;

Kamata, M. ;

Mizukawa, I. ;

Watanabe, A. ;

Agematsu, A. ;

Nagata, M. ;

Fukaya, S. ;

Hayashi, K. ;

Fukuyasu, A. ;

Tanaka, T. ;

Ishikawa, T. ;

Ohnishi, T. ;

Tada, Y. .

BRITISH JOURNAL OF DERMATOLOGY, 2019, 181 (05) :1083-1085

← 1 2 →